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Placental and maternal sFlt1/PlGF 
expression in gestational diabetes 
mellitus
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Gestational diabetes mellitus (GDM) and preeclampsia (PE) are both characterized by endothelial 
dysfunction and GDM women have higher incidence of PE. The placenta plays a key role in PE 
pathogenesis but its contribution to PE during GDM remains unclear. Herein, we compared placental 
and maternal blood anti-angiogenic soluble fms-like tyrosine kinase-1 (sFlt1) and pro-angiogenic 
Placental Growth Factor (PlGF) expressions in GDM and GDM-PE pregnancies compared to controls 
(CTRL) and PE cases. Electrochemiluminescence immunoassays showed a significantly higher 
maternal blood sFlt1/PlGF values in GDM-PE relative to CTRL and GDM pregnancies. We reported 
that placental PlGF gene expression was significantly decreased in GDM, PE and GDM-PE relative to 
CTRL. However, PlGF protein levels were significantly increased in GDM and GDM-PE relative to CTRL 
and PE placentae. Finally, sFlt1 gene expression was significantly increased in PE relative to CTRL, 
GDM and GDM-PE placentae. In contrast, sFlt1 protein expression was significantly decreased in 
GDM-PE relative to CTRL, GDM and PE placentae. Finally, higher sFlt1/PlGF ratio in GDM-PE maternal 
blood suggest that sFlt1 overproduction is related to PE onset also in GDM pregnancies even though 
characterized by a less severe endothelial dysfunction in terms of angiogenic biomarkers.
Human pregnancy is characterized by a series of complex morphological and functional maternal adaptations 
to support fetal growth and development. Among these, a physiological rise in insulin resistance gradually 
starts during the second half of pregnancy and rapidly decreases after  birth1. This physiological modification 
is designed to limit maternal glucose uptake in order to shunt an adequate nutrient supply to the growing fetus 
and it is believed to arise from increased maternal adiposity and the effects of placental  hormones2. Maternal 
adiposity enhances insulin resistance through an increase in lipolysis and free fatty acids, leading to compensa-
tory hyperinsulinemia, which in turn increases adipogenesis and inflammatory adipokines and increases insulin 
 resistance3. Human Placental Lactogen (hPL), whose levels increase during the second half of pregnancy, medi-
ates pregnancy insulin resistance by serving as insulin  antagonist2. During normal gestation, women are able to 
counteract peripheral insulin resistance with a significant increase of their basal and nutrient-stimulated insulin 
secretion from pancreatic b  cells1, thus explaining why blood glucose levels are minimally altered during physi-
ological  pregnancy1. However, some pregnant women are not able to intensify insulin secretion thus developing 
Gestational Diabetes Mellitus (GDM). The majority of GDM women present pancreatic β cell dysfunction that 
occur on a background of chronic insulin resistance. Indeed, the physiological insulin resistance is partially addi-
tive to a background of chronic insulin resulting in a greater insulin resistance than normal pregnant  women4. 
GDM is defined as any degree of glucose intolerance that it is first recognized during pregnancy, mostly in the 
second/third trimester of  gestation5. GDM, if not adequately recognized and treated, is associated with high 
maternal and fetal morbidity, recurring as Type II diabetes months or years after pregnancy. The placenta is 
exposed as well to hyperglycemia during GDM but it mounts adaptive responses such as enhancing placental 
mitochondrial fusion to compensate hyperglycemia-induced mitochondrial damage as well as to support physi-
ological fetal  development6,7. Overall, GDM placentae are in a pro-angiogenic state, presenting more endothelial 
cells and placental blood vessels per chorionic  villi8.
The disruption of insulin signaling resulting in insulin resistance is also implicated in Preeclampsia (PE) 
associated placental endothelial  dysfunction9,10. PE is a severe multifactorial pregnancy-induced syndrome that 
is the main causes of fetal-maternal mortality and morbidity worldwide. PE anomalies are mainly mediated by 
placental release of proinflammatory cytokines, chemokines and anti-angiogenic  factors11. Among these, the 
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imbalance between anti-angiogenic soluble FMS-like tyrosine kinase-1 (sFlt1) and pro-angiogenic Placental 
Growth Factor (PlGF) is believed to be pivotal for endothelial damage  onset12,13. During normal placenta devel-
opment, Vascular Endothelial Growth Factor (VEGF) and PlGF regulate trophoblast growth and differentiation, 
villous angiogenesis, and remodeling of maternal spiral  arteries12,13. In PE, placental oxidative  stress14,15 triggers 
the overexpression of anti-angiogenic sFlt1 that acts as a potent scavenger of both VEGF and PlGF, thus prevent-
ing their binding to cell membrane  receptors16–18. Indeed, abnormally elevated concentrations of placental and 
circulating sFlt1 inhibit free vascular endothelial growth factor and PlGF, thus causing the aberrant placental 
angiogenesis and generalized endothelial dysfunction typical of PE  syndrome16,18.
Previous findings suggested that increased oxidative  stress19, endothelial  dysfunction20,21 and angiogenic 
 imbalance20,22 were altered in both GDM and PE. However, it is difficult to define whether anomalies in sFlt1/
PlGF were derived from a common etiology or were responses to different pathogenic mediators. GDM and 
PE share several risk factors, including advanced maternal age, nulliparity, twin pregnancy, ethnicity and pre-
pregnancy  obesity23,24. GDM itself is a risk factor for PE and  viceversa25–29. However, the relationship between 
pro-/anti-angiogenic factors and PE in women with GDM has been poorly  explored30–32. From a physiopatho-
logical point of view, we expected GDM-PE to behave similarly to PE. According to this hypothesis, the sFlt-1/
PlGF balance should be altered in GDM-PE patients, thus identifying GDM women at risk for PE develop-
ment. sFlt-1 and PlGF as biomarkers have been largely studied in relation to PE since variations in their ratio 
appear before preeclampsia clinical  signs18,33–35. Nevertheless, the complex interaction between the sFlt-1 and 
PlGF maternal–fetal–placental axis in GDM to predict PE has never been addressed. In the present study, we 
investigated placental and maternal blood sFlt1/PlGF expressions in GDM and GDM-PE pregnancies cases in 
order to explore a possible differential regulation of angiogenic molecules compared to CTRL and PE patients.
Results
Study population. Clinical features of the study population are reported in Table 1. CTRL (n = 17), GDM 
(n = 27), GDM-PE (n = 22) and PE (n = 17) pregnancies are comparable for maternal age, percentage of nul-
liparous women, cigarette smokers and alcohol consumers (p > 0.05). As expected, gestational age at delivery 
and neonatal weights are significantly lower in GDM-PE and PE relative to CTRL and GDM groups (p < 0.01). 
No significant differences are found between GDM-PE and PE (p > 0.05). Placental weight is significantly lower 
in GDM-PE and PE relative to CTRL groups but no significant differences are reported among GDM-PE and 
GDM (p > 0.05). Pregnancies belonging to the GDM-PE and PE groups present significantly increased systolic/
diastolic blood pressure (p < 0.01) and proteinuria (p < 0.01) relative to both GDM and PE. Abnormal umbili-
cal (p < 0.05) and/or uterine arteries (p < 0.05) Doppler velocimetry, which are signs of fetal-placental compro-
mise, are reported in GDM-PE and PE relative to CTRL and GDM groups. The percentage of women with pre-
pregnancy BMI ≥ 25 and ≥ 30 are significantly higher in GDM (p = 0.03 and p = 0.02), GDM-PE (p = 0.01 and 
p < 0.01) and PE (p = 0.01 and p = 0.02) groups relative to CTRL, while BMI at delivery is significantly increased 
in GDM-PE relative to CTRL (p < 0.01). No differences are found in haematocrit and ALT levels, while platelet 
and AST decreased in PE relative to GDM (p = 0.02 and p = 0.04, respectively). A slight increase of fibrinogen 
levels is reported in GDM (519.7 ± 24.7) and GDM-PE (522.1 ± 22.7) relative to CTRL (456.7 ± 19.5) and PE 
(486.9 ± 20.6) patients (p > 0.05). Increased intensive care admission is reported in GDM-PE and PE pregnancies 
relative to CTRL (p = 0.01 and p < 0.01 respectively) and GDM (p = 0.04 and p = 0.01 respectively). No significant 
differences in the female/male neonatal sex distribution are observed between groups (p > 0.05).
sFlt1/PlGF ratio pattern in maternal serum of CTRL,GDM, GDM-PE and PE pregnancies. Pre-
vious studies reported increased sFlt1/PlGF ratio in maternal blood of PE relative to control  pregnancies34,36. 
Herein, we evaluated whether anomalous maternal serum sFlt1, PlGF and sFlt1/PlGF ratios are present in 
GDM and GDM-PE pregnancies relative to our previously published data in CTRL and  PE33. Clinical features 
of CTRL and PE patients enrolled are reported in Rolfo et al.33. Gestational ages at maternal blood collection are 
comparable between CTRL (34.5 ± 3.25 weeks of pregnancy), GDM (32.8 ± 1.3 weeks of pregnancy), GDM-PE 
(31.9 ± 1 weeks of pregnancy) and PE (30.6 ± 5.12 weeks of pregnancy) (p > 0.05). PlGF serum levels are sig-
nificantly increased in CTRL (median: 279.3 pg/ml, range 50.9–1262) and GDM (median: 220.6 pg/ml, range 
72.1–639.1) relative to GDM-PE (median: 57.4 pg/ml, range 41.9–313.63) and PE (median: 32.6 pg/ml, range 
11–86.9) (Fig. 1a, CTRL vs GDM-PE, p = 0.007, 7.2 Fold Increase; CTRL vs PE, p < 0.0001, 12.6 Fold Increase; 
GDM vs GDM-PE, p = 0.01, 4.7 Fold Increase; GDM vs PE, p < 0.0001, 8,3 Fold Increase). This is accompa-
ined by significant decrased sFlt1 levels in CTRL (median: 2499 pg/ml, range 823–14,833) and GDM (median: 
2345.5  pg/ml, range 1477–10,060) relative to GDM-PE (median: 9471,5  pg/ml, range 6532–12,411) and PE 
(median: 13,519.5 pg/ml, range 6059–34,398) (Fig. 1b, CTRL vs GDM-PE, p = 0.05, 2.8 Fold Increase; CTRL 
vs PE, p < 0.0001, 4.3 Fold Increase; GDM vs GDM-PE, p = 0.05, 3.64 Fold Increase; GDM vs PE, p < 0.0001, 
8,3 Fold Increase p = 0.05, 5.48 Fold Increase) resulting in significantly higher sFlt1/PlGF values in GDM-
PE (median: 166.7  pg/ml, range 45.4–330.8) and PE (median: 435.79  pg/ml, range 160.90–1153.53) relative 
to CTRL (median: 9.36, range 1.38–126.83) and GDM pregnancies (median: 10.7, range 2.8–53.3) (Fig. 1c,d, 
CTRL vs GDM-PE, p = 0.02, 12.1 Fold Increase; CTRL vs PE, p < 0.0001, 32.4 Fold Increase; GDM vs GDM-PE, 
p < 0.001, 11.2 Fold Increase; GDM vs PE, p < 0.0001, 22.7 Fold Increase). Even thought sFlt1/PlGF values in 
GDM-PE patients are significantly higher relative to CTRl and GDM, they are significanlty decreased relative to 
PE (Fig. 1c,d, p < 0.0001, 2.69 Fold Increase).
Correlation of clinical characteristics with serum sFlt-1 and PlGF levels in GDM and GDM-PE 
pregnancies. In order to evaluate whether maternal serum sFlt1 and PlGF variability between GDM and 
GDM-PE groups could depend on clinical features, we calculated Pearson correlation coefficient. We did not 
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CTRL (n = 17) GDM (n = 27) GDM-PE (n = 22) PE (n = 17) p value
Nulliparus (%) 29 30 45 53 > 0.05
Maternal age at delivery 
(years) 31.8 ± 1.1 (24–40) 34.3 ± 0.8 (27–44) 34.9 ± 0.9 (23–43) 32.6 ± 1.1 (26–40) > 0.05
Caucasian ethnicity (%) 100 100 95 100 > 0.05
Cigarette smoking (%) 5.9 11.1 13.6 0 > 0.05
Alcohol (%) 0 0 0 0 > 0.05
Pre-pregnancy BMI 22.7 ± 0.8 27.4 ± 1.3 30.6 ± 2.6# 26.8 ± 1.1 GDM-PE vs CTRL: p = 0.001
Pre-pregnancy BMI 
≥ 25 kg/m2 (%) 24 52
# 64# 65#
GDM-PE vs CTRL: 
p = 0.01
GDM vs CTRL: p = 0.049
PE vs CTRL: p = 0.01
Pre-pregnancy BMI 
≥ 30 kg/m2 (%) 0 26
# 55*# 29#
GDM-PE vs GDM: 
p = 0.049
GDM-PE vs CTRL: 
p < 0.001
GDM vs CTRL: p = 0.02
PE vs CTRL: p = 0.01
Delivery BMI (kg/m2) 27.2 ± 0.8 30.5 ± 1.2 33.8 ± 1.6# 30.4 ± 1.1 GDM-PE vs CTRL: p = 0.005
Systolic blood pressure 
(mm Hg) 122.5 ± 2.3 129.7 ± 2.2 167 ± 5.1*
# 163.4 ± 6.1*#
GDM-PE vs GDM: 
p < 0.001
GDM-PE vs CTRL: 
p < 0.001
PE vs GDM: p < 0.001
PE vs CTRL: p < 0.001
Diastolic blood pressure 
(mm Hg) 71.4 ± 2.1 75.1 ± 1.5 100.7 ± 2.5*
# 99.1 ± 3.6*#
GDM-PE vs GDM: 
p < 0.001
GDM-PE vs CTRL: 
p < 0.001
PE vs GDM: p < 0.001
PE vs CTRL: p < 0.001
Proteinuria (g/24 h) Absent 0.03 ± 0.03 2.30 ± 0.5*# 3.05 ± 0.7*#
GDM-PE vs GDM: 
p < 0.001
GDM-PE vs CTRL: 
p = 0.001
PE vs GDM: p < 0.001
PE vs CTRL: p < 0.001
A/REDF (%) 0 0 18.2* 29.4*#
GDM-PE vs GDM: 
p = 0.01
PE vs GDM: p = 0.02
PE vs CTRL: p = 0.03
Pathological uterine 
doppler (%) 0 0 18.2* 41.2*
#
GDM-PE vs GDM: 
p = 0.03
PE vs GDM: p = 0.001
PE vs CTRL: p = 0.003
Therapy (%) Absent Diet: 63Insulin: 37
Diet: 73
Insulin: 27 Absent > 0.05
Caesarian section (%) 53 52 95.4*# 76.5
GDM-PE vs GDM: 
p = 0.001
GDM-PE vs CTRL: 
p = 0.002
Hematocrit (%) 34.9 ± 0.7 35.6 ± 0.7 33.6 ± 0.8 34.2 ± 0.7 p > 0.05
Platelet (× 103/μl) 244.7 ± 13.1 250.6 ± 14.3 252.1 ± 17.1 189.1 ± 18.2* PE vs GDM: p = 0.048
AST (U/l) 17.3 ± 0.7 15.0 ± 0.7 22.2 ± 3.3 33.6 ± 9.4* PE vs GDM: p = 0.04
ALT (U/l) 11.4 ± 1.0 11.6 ± 1.0 18.4 ± 3.7 27.6 ± 9.2 p > 0.05
Fibrinogen (mg/dl) 456.7 ± 19.5 519.7 ± 24.7 522.1 ± 22.7 486.9 ± 20.6 p > 0.05
Gestational age at deliv-
ery (weeks) 39.4 ± 0.2 (36–41) 38.2 ± 0.3 (33–41) 34.6 ± 0.7*
# (28–40) 33.9 ± 1*# (26–39)
GDM-PE vs GDM: 
p = 0.004
GDM-PE vs CTRL: 
p = 0.001
PE vs GDM: p < 0.001
PE vs CTRL: p < 0.001
Placental weight (g) 556.5 ± 20.7 514.1 ± 22.3 417.3 ± 31# 380.3 ± 38.3*#
GDM-PE vs CTRL: 
p = 0.007
PE vs GDM: p = 0.009
PE vs CTRL: p = 0.001
Birth weight (g) 3346.2 ± 92.8 3112 ± 100 2108.6 ± 198.4*# 1866.3 ± 237.3*#
GDM-PE vs GDM: 
p < 0.001
GDM-PE vs CTRL: 
p < 0.001
PE vs GDM: p < 0.001
PE vs CTRL: p < 0.001
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Table 1.  Clinical features of the study population. Comparisons of CTRL, GDM, GDM-PE and PE and PE 
pregnancies clinical features. Values are expressed as mean ± Standard Error (SE) and percentage. Comparisons 
among groups were done by ANOVA, which, if significant, was followed by pairwise analysis using the 
Bonferroni method. Categorical variables are presented as frequencies (percentages) and the comparison 
between different groups was done with Chi-Square Test. Significant differences (p ≤ 0.05): #differences 
indicating a significant effect compared with CTRL; *differences indicating a significant effect compared with 
GDM; §differences indicating a significant effect compared with PE and ^differences indicating a significant 
effect compared with GDM-PE. BMI body mass index, A/REDF absent/reverse end diastolic flow, AST 
aspartate aminotransferase, ALT alanine aminotransferase, NICU Neonatal Intensive Care Uni.
CTRL (n = 17) GDM (n = 27) GDM-PE (n = 22) PE (n = 17) p value
NICU admission (%) 0 7.4 31.8*# 41.2*#
GDM-PE vs GDM: 
p = 0.03
GDM-PE vs CTRL: 
p = 0.01
PE vs GDM: p = 0.01
PE vs CTRL: p = 0.003
Fetal sex (%)
Male 29.4 59.3 40.0 35.0 > 0.05
Female 70.6 40.7 60.0 65.0 > 0.05
Figure 1.  Maternal Blood PlGF, sFlt1 and sFlt1/PlGF ratio in CTRL, GDM, GDM-PE and PE pregnancies. 
(a) PlGF and (b) sFlt1, (c) sFlt1/PlGF ratio relative to fold increases and (d) boxplot of calculated sFlt1/PlGF 
ratios in CTRL, GDM, GDM-PE and PE patients as assessed by Elecsys methodology. Statistical significance has 




Scientific Reports |         (2021) 11:2312  | https://doi.org/10.1038/s41598-021-81785-5
www.nature.com/scientificreports/
find any significant correlation except for placental weigh in GDM pregnancies that positively correlated with 
sFlt1 maternal values (r = 0.76, p = 0.045).
sFlt1 and PlGF expression in CTRL, GDM, GDM-PE and PE placentae. Next, we analyzed sFlt1 
and PlGF expression levels in placentae from CTRL, GDM, GDM-PE and PE pregnancies. Pro-angiogenic PlGF 
mRNA expression is decreased in GDM (p = 0.03, 1.8 Fold Decrease), GDM-PE (p < 0.01, 7.1 Fold Decrease) and 
PE (p = 0.05, 1.5 Fold Decrease) relative to CTRL placentae (Fig. 2a). Moreover, GDM-PE placentae showed sig-
nificantly reduced PlGF gene down-regulation relative to both GDM (p < 0.01, 4 Fold Decrease) and PE (p < 0.01, 
1.2 Fold Decrease) ones (Fig. 2a). In contrast, PlGF protein levels are increased in GDM and GDM-PE relative to 
CTRL (GDM, p = 0.03, 1.3 Fold Increase; GDM-PE, p = 0.2, 1.25 Fold Increase) and PE (GDM, p = 0.04, 1.5 Fold 
Decrease; GDM-PE, p = 0.01, 1.25 Fold Decrease) placentae (Fig. 2b).
As expected, we reported a significant increase of anti-angiogenic sFlt1 gene expression in PE relative to 
CTRL (p = 0.05, 2 Fold Increase), GDM (p = 0.03, 2.4 Fold Increase) and GDM-PE (p = 0.04, 2.4 Fold Increase) 
placentae (Fig. 2c) while no significant differences are reported in GDM-PE relative to CTRL and GDM (p > 0.05). 
While there are no differences in placental sFlt-1 protein expression between GDM-PE and CTRL (p > 0.05), a 
significant decrease was seen in GDM-PE relative to GDM (p = 0.041) and PE (p = 0.035) (Fig. 2d).
Discussion
GDM and PE pregnancies share some pathognomonic anomalies, including endothelial dysfunction and angio-
genic imbalance. There are increased evidences for the role of placental angiogenic biomarkers in predicting 
obstetrical complications associated with placental  dysfunction37–39. However, there are limited data on angio-
genic factors in GDM patients. In the present study, we showed differential sFlt1/PlGF expression profiles in 
pregnancies complicated by GDM, PE and GDM with superimposed PE. We reported that sFlt1/PlGF ratio 
Figure 2.  PlGF and sFlt1 gene and protein expression levels in CTRL, GDM, GDM-PE and PE placentae. 
(a) mRNA and (b) protein expression of PlGF in CTRL, GDM, GDM-PE and PE placentae; (c) mRNA and 
(d) protein expression of sFlt1 in CTRL, GDM, GDM-PE and PE placentae. Statistical significance has been 
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in GDM-PE maternal serum was significantly increased relative to CTRL and GDM samples but decreased 
sFlt1/PlGF values were detected in GDM-PE relative to PE pregnancies. From the placenta point of view, anti-
angiogenic sFlt1 gene expression increased in PE placentae relative to CTRL, GDM and GDM-PE but decreased 
sFlt1 protein levels were observed in GDM-PE relative to GDM and PE. Pro-angiogenic PlGF mRNA expression 
was decreased in GDM, PE and GDM-PE relative to CTRLs while PlGF protein levels were increased in GDM 
and GDM-PE relative to CTRLs and PE. Therefore, when the finely tuned placental balance between pro- and 
anti-angiogenic molecules is altered in GDM pregnancies, deleterious consequences on endothelial function in 
the maternal vasculature lead to PE development, as confirmed by increased maternal blood sFlt1/PlGF ratio in 
GDM-PE,. Since it has been described that sFlt1 and PlGF alterations appear before clinical  signs18,35, they may 
serve as important PE predictive markers to alert clinicians to increase GDM patients monitoring.
Previous studies documented a link between sFlt1/PlGF ratio and the occurrence of pregnancy endothelial-
based disorders other than PE as early-onset IUGR 18. Therefore, we investigated whether sFlt1 and PlGF could 
be used as biomarkers of endothelial dysfunction in both GDM and GDM-PE. The lowest sFlt1/PlGF ratio was 
reported in the GDM group (median: 10.7 pg/ml, range 2.8–53.3) and it was comparable with our previously 
published data in physiological pregnancies (median: 9.36 pg/ml, range 1.4–126.8)33. In line with the present 
results, we described the absence of maternal serum sFlt1/PlGF alterations in Chronic Kidney Disease (CKD) 
pregnancies, a condition that, as GDM, shares with preeclampsia several clinical symptoms but it is character-
ized by a different  pathogenesis33. Since the placenta is the main source of circulating pro- and anti-angiogenic 
molecules during  pregnancy36, we suggested that in CKD pregnancies the endothelial damage was limited to 
the kidney and, thus, of maternal  origin33. Therefore, GDM vascular damage could not affect the fetal-placental 
unit. We reported comparable placental and birth weights as well as equivalent uterine/umbilical Doppler in 
GDM and CTRL groups, thus confirming our hypothesis of a healthy fetal-placental unit in GDM pregnancies. 
Nevertheless, we detected higher sFlt1/PlGF ratio values in maternal blood of GDM-PE pregnancies relative 
to GDM. Since it is widely accepted that high sFlt1/PlGF ratio directly correlates with  PE33,38, we expected to 
obtain similar ratio values in GDM-PE and PE pregnancies. However, we showed that sFlt1/PlGF values (median: 
166.7 pg/ml, range 45.4–330.8) were lower in GDM-PE relative to those previously published in PE pregnan-
cies (median: 435.79 pg/ml, 160.9–1153.5)33 although some cases presented values higher than the established 
cut-off levels of 150 used to predict  PE34. As mentioned above, the placenta plays a key role in sFlt1 and PlGF 
production and a defective placentation, typical of PE, significantly contributes to increased circulating anti-
angiogenic sFlt1  levels40. sFlt1 increase lead to decreased maternal PlGF  concentration30,35,41,42 and sFlt1 levels 
were directly correlated to PE  severity18,43–45. In the present study, the reduced PE severity in GDM patients was 
confirmed by the reduced percentage of pathological uterine/umbilical Doppler and the increased weights of 
fetal-placental unit that we reported in GDM-PE relative to PE pregnancies. Decreased maternal PlGF serum 
levels in preeclampsia have been attributed to reduced placental production and to the inhibition of free PlGF 
by over-expressed circulating  sFlt146. We observed a positive correlation between placental weight and sFlt1 but 
not PlGF serum concentrations in GDM patients, thus excluding that PlGF placental over-production was due 
to higher placental cells number.
sFlt1/PlGF ratio increase in GDM-PE is consistent with previously published retrospective analysis in diabetic 
patients. Yu and colleagues demonstrated that women with type 1 diabetes (DM1) and PE had increased sFlt1, 
decreased PlGF and increased sFlt1/PlGF ratio compared with  controls39. Three others cohort studies investigat-
ing a preeclamptic population with preexisting diabetes, reported increased sFlt1, decreased PlGF and increased 
sFlt1/PlGF ratio before PE onset relative to non PE  women47–49.
Fetal hyperglycemia, hyperinsulinemia, hypoxia as well as placental mitochondrial fusion that pro-
mote placental ‘anabolism’ are associated with placental hypervascularisation in GDM compared to normal 
 pregnancies7,50,51. In accordance with an environment that promotes vascularization, in GDM placentae we 
described no differences in placental sFlt1 expression while we reported a significant increase of pro-angio-
genic PlGF relative to CTRL. Accordingly, Pietro L and colleagues described that the hyperglycemic placenta 
over-expressed the pro-angiogenic mediator  VEGF52. This mechanism could counteract the widespread sFlt1/
diabetes-mediated endothelial dysfunction typical of GDM to maintain maternal–fetal homeostasis as previously 
suggested by Calderon et al.53. Abbade et al. confirmed the placenta protective role from the harmful effects of 
GDM. They reported in GDM pregnancies that a reduced placental ceramide facilitate anabolism in the fetal-
placental unit by upregulating the acid ceramidase ASAH1, an enzyme involved in the degradation of ceramide 
into sphingosine and fatty acids, thus avoiding the enhanced mitochondrial fission and cell death typical of  PE7.
In GDM-PE, sFlt1 down-regulation could exacerbate the mild hypervascularization induced by PlGF overex-
pression on placental vasculature. Our data are consistent with Shainker et al. that reported lower sFlt1 expression 
in hyperperfused placentae, suggesting a functional role for sFlt1 in invasive placental  implantation54. Differently 
by PE, where high sFlt1 expression is associated with shallow placentation and placental  hypoperfusion55,56, 
placental sFlt1 downregulation in GDM-PE could result in invasive placentation and deeper implantation along 
with hyperperfusion as previously suggested by McMahnon et al.57. In addition, decreased sFlt1 expression 
might be an adaptation to increased blood  flow58 and it may allow vascular growth factors to increase placental 
angiogenesis in accordance with the developing fetus  needs59. Therefore, increased feto-placental weight and 
decreased percentage of pathological uterine/umbilical Doppler, Apgar < 7 at 5 min and of NICU admission that 
we reported in GDM-PE to PE provided evidences of this possible placental adaptation attempt.
It is widely accepted that proteinuria, typical hallmark of PE, is a consequence of glomerular damage caused by 
vascular endothelium destruction. The same mechanism was suggested to be involved in glomerular damage in 
patients with  GDM60. In GDM-PE patients, where sFlt1/PlGF ratio was lower relative to previously published data 
in  PE33, we reported increased proteinuria relative to GDM and CTRL. As expected, GDM-PE patients presented 
lower proteinuria relative to PE. Finally, proteinuria in GDM, characterized by sFlt1/PlGF ratio comparable to 
CTRL, was similar to that of physiological pregnancies.
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No differences were found in sFlt1 and PlGF levels and sFlt1/PlGF ratio in GDM vs CTRL patients, thus 
indicating a physiological behaviour of GDM pregnancies in terms of circulating angiogenesis biomarkers. 
In line with these results, we reported higher sFlt1/PlGF values in GDM-PE and PE sera relative to CTRL and 
GDM groups. Importantly, GDM-PE sFlt1/PlGF ratio were significantly lower relative to PE ones. Overall, our 
results suggest a less severe endothelial dysfunction in gestational diabetes relative to preeclampsia. Given the 
small number of patients enrolled, further analyses are required to confirm our data. A broader recruitment 
is necessary to provide better insights into GDM-PE physiopathology as well as a prospective study aimed at 
performing sFlt1/PlGF analyses during all three trimesters of pregnancy.
Conclusions
This is the first time to our knowledge that the association among GDM, PE and placental biomarkers was 
investigated. The strength of our study was the identification of a differential sFlt1/PlGF expression in GDM 
and GDM-PE relative to CTRL and PE pregnancies. Further strengths are the precise definitions of GDM, using 
universal OGTT screening as indicated by  IADPSG61 and  WHO62, and PE in accordance to ACOG  guidelines63. 
Several studies supported the imbalance of placental pro- and anti-angiogenic factors as a plausible mechanism 
for PE endothelial  dysfunction18. Our data suggest that when this finely tuned mechanism is altered, GDM 
pregnancies developed a more severe endothelial damage evolving in GDM-PE, as confirmed by increased 
maternal blood sFlt1/PlGF ratio. Our study expanded the knowledge about developmental origin of GDM and 
GDM-PE diseases but further investigations are required to clarify the potential role of sFlt1/PlGF ratio for early 
identification of GDM patients at risk for PE.
Materials and methods
Ethics statement. The study was conducted at the Gynaecology and Obstetrics Unit U2 of the Città della 
Salute e della Scienza-Sant’Anna University Hospital, University of Turin (Turin, Italy). The study was performed 
in adherence to the Declaration of Helsinki. After patient’s recruitment and informed consent obtainment in 
accordance with the ethics guidelines of the O.I.R.M-Sant’Anna Hospital Ethics Committee (approval of the 
Ethics Committee of O.I.R.M.-Sant’Anna Hospital and “Ordine Mauriziano di Torino” number n.209; protocol 
39226/C.27.1 04/08/09), placentae and blood samples were collected.
Study population and sample collection. The study was conducted on 83 singleton pregnancies cat-
egorized as follow: 17 physiological term controls (CTRL), 27 GDM, 22 GDM complicated by PE (GDM-PE) 
and 17 PE. Physiological controls were obtained from normal term healthy singleton pregnancies that did not 
show any which are signs of of PE, GDM or other placental disease. We did not use “gestational age-matched” 
controls pregnancies since pre-term deliveries cannot be considered physiological. Patients with cardiovascular 
disorders, diabetes, infections, kidney disease, congenital malformations and chromosomal anomalies (number 
and/or structure) were excluded.
GDM was diagnosed by oral glucose tolerance test with 75 g of glucose (OGTT 75 g). GDM screening was 
recommend between 16 and 18 weeks of gestation for women with at least one of the following conditions: 
previous GDM, pre-pregnancy body mass index (BMI) ≥ 30 kg/m2, plasma glucose values at the beginning of 
pregnancy (within the first trimester) between 100 and 125 mg/dl (5.6–6.9 mmol/l). In case of normal OGTT 
results, the test was repeated at 24–28 weeks of gestation. The risk factors considered at 24–28 weeks of gestation 
were: age ≥ 35 years, pre-pregnancy BMI ≥ 25 kg/m2, fetal macrosomia in a previous pregnancy (≥ 4.5 kg), family 
history of diabetes (first-degree relative with type 2 diabetes), family origin from areas at high prevalence of dia-
betes. Women with one or more plasma glucose values above the established thresholds (≥ 92 mg/dl at baseline, 
≥ 180 mg/dl after 1 h from the load, ≥ 153 mg/dl after 2 h from the load) were diagnosed as  GDM64,65. In our 
cohort, all the GDM patients routinely received dietary counseling and nutritional recommendations in line with 
guidelines (carbohydrates 45% total energy, rapidly absorbed sugars < 10% total energy, proteins 18–20% total 
energy, fats 35% total energy, at least 20–25 g/day fiber intake, no alcohol)64. Furthermore, 30 min daily moderate 
exercise was recommended (i.e. brisk walking). Patients were instructed to self-monitor finger-prick capillary 
blood glucose (fasting and 1 h after meal with glycemic targets of < 95 and < 130 mg/dl, respectively) at least four 
times per day. Insulin treatment was prescribed in presence of hyperglycemia in accordance with  guidelines66.
PE was defined as a blood pressure elevation (≥ 140/90 on two occasions four hours apart or ≥ 160/110 once), 
after 20 weeks of gestation in previously normotensive women, with proteinuria (≥ 300 mg on 24 h protein or 
> 0.3 protein/creatinine ratio) or any of the following if proteinuria not presents: platelets < 100,000; creatinine 
> 1.1 (or doubling of creatinine in absence of other renal disease); doubling of AST or  ALT67.
During the third trimester of pregnancy (31–34 weeks), maternal venous blood samples (5 mL) were col-
lected into Vacutainer tubes without anticoagulant. Serum was separated by centrifugation immediately after 
clotting (3000 rpm at 4 °C for 20 min within 3 h from collection) and stored at − 20 °C until assayed. Placental 
tissue biopsies were randomly collected from the central placental area and snap frozen within one hour after 
delivery. Calcified, necrotic and seriously damaged areas were excluded from collection. Placental samples were 
next processed for mRNA and protein isolation. It was not possible to collect for all pregnant women enrolled 
both placental and maternal blood sample. Therefore the overall number of patients per group in Table 1 were 
higher than those reported in Figs. 1 and 2.
sFlt1 and PlGF assays. sFlt1 and PlGF serum levels in CTRL, GDM, GDM-PE and PE pregnancies were 
determined by validated and commercially available electrochemiluminescence immunoassays (Elecsys, Roche, 
Penzberg, Germany) using a Cobas-e-411 immunoanalyzer and following the manufacturer’s instructions. Since 
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CTRL (n = 38) and PE (n = 34) maternal blood samples are the same of our published  work33, we included these 
sFlt1/PlGF values in the present  analysis33.
RNA isolation and real time PCR. In parallel, total RNA was isolated from frozen placental biopsies 
using TRI reagent (Sigma-Aldrich, Milano, Italy) according to manufacturer instructions and next treated with 
DNAse I to remove genomic DNA contamination. 3 µg of total RNA were reverse transcribed using a random 
hexamers approach (Fermentas Europe, St. Leon-Rot., Germany). Gene expression levels of PlGF and sFlt1 were 
quantified by Real-time PCR using specific TaqMan primers and probes following manufacturer’s protocol (Life 
Technologies). TaqMan primers and probes for ribosomal 18S and PlGF were purchased from Applied Biosys-
tems as TaqMan Gene Expression Assays. sFlt-1 primers and probe were designed as previously described by 
Nevo et al.68 and purchased from Applied Biosystems as Custom Gene Expression Assays. For the relative quan-
titation, PCR signals were compared among groups after normalization using ribosomal 18S RNA expression as 
internal reference (Life Technologies) whose expression remains stable across patients. Relative expression and 
fold change were calculated according to Livak and  Schmittgen69.
sFlt1 and PlGF enzyme-linked immunosorbent assay (ELISA). Total proteins were isolated from 
placental biopsies using 1X Radio Immuno-precipitation Assay (RIPA) buffer supplemented with Protease 
Inhibitors. Quantitative measurement of PlGF (R&D System, Italy) and sFlt1 (R&D System, Italy) placental lev-
els were determined using commercially available competitive ELISA kits according to manufacturer’s instruc-
tion. Briefly, samples were incubated in 96-well plate precoated with a capture antibody directed against PlGF 
or sFlt1 for 2 h. Wells were then washed three times and incubated with a secondary antibody against PlGF and 
sFlt1 conjugated to horseradish peroxidase. The plates were then washed again three times, substrate solution 
containing  H2O2 and tetramethylbenzidine was added, and optical density was determined at 450 nm. All assays 
were done in duplicate, and the protein levels were calculated using a standard curve derived from known con-
centrations of the respective recombinant proteins.
Statistical analysis. All data are represented as mean ± standard error (SE) for parametric and as median 
and range for non-parametric data. Data were tested for normality with the Shapiro–Wilk test prior to statisti-
cal analysis. Comparison among groups was performed by analysis of variance. Bonferroni’s test was used for 
post-hoc comparisons between two groups of parametric data, while Kruskal–Wallis test was used for non-
parametric data. Categorical variables are presented as frequencies (percentages) and the comparison between 
different groups was done with Chi-Square Test. In GDM and GDM-PE groups, we also investigated whether 
significant differences in clinical caracheristics were correlated with serum sFlt-1 and PlGF levels by calculating 
Pearson correlation coefficient. Statistical test were carried out using SPSS Version 25 statistical software and 
significance was accepted at p < 0.05.
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